Trial Profile

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Renal cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
Acronyms AIM-NIVO

Most Recent Events

21 Aug 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2026.
21 Aug 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Aug 2026.
01 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com